Document ID: chunk:federal_register_of_legislation:F2018L01177:reg:9:p3
Version: federal_register_of_legislation:F2018L01177
Segment Type: reg
Provision Reference: reg 9 (pt 3/3)
Character Range: 9167–10284

lewisite.

            Note 3: Examples of acute nasal symptoms or signs include rhinorrhoea, and the inflammation, oedema, ulceration or haemorrhage of the nasal mucosa.
(18)      for sinusitis affecting the maxillary sinus only, having a specified dental condition affecting the tissues adjacent to the affected maxillary sinus at the time of the clinical worsening of sinusitis;
Note: specified dental condition is defined in the Schedule 1 - Dictionary.
(19)      for sinusitis with nasal polyps only, using a drug belonging to the nonselective (COX-1 and COX-2 inhibitors) nonsteroidal anti-inflammatory class of drugs, at the time of the clinical worsening of sinusitis;
            Note: Nonselective (COX-1 and COX-2 inhibitors) nonsteroidal anti-inflammatory class of drugs:
              (a) includes drugs such as aspirin, diclofenac, ibuprofen, indomethacin, ketoprofen, ketorolac, mefanamic acid, paracetamol, piroxicam and sulindac; and

              (b) excludes drugs such as celecoxib, etoricoxib, meloxicam and parecoxib.
(20)      inability to obtain appropriate clinical management for sinusitis.